Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in

Cinzia A Ventura1, Silvana Tommasini, Emanuela Crupi

  • 1Pharmaco-Chemical Department, University of Messina, Messina, Italy. cventura@pharma.unime.it

Insights

Chitosan microspheres offer sustained release of moxifloxacin for intrapulmonary administration. Crosslinked microspheres effectively reduced drug absorption through bronchial epithelial cells, indicating potential for controlled pulmonary drug delivery.

Area of Science:

  • Pharmaceutics
  • Biomaterials Science
  • Drug Delivery

Background:

  • Chitosan microspheres are investigated for sustained drug release.
  • Pulmonary administration requires optimized drug delivery systems.
  • Moxifloxacin is an antibiotic used for respiratory infections.

Purpose of the Study:

  • To prepare and characterize moxifloxacin-loaded chitosan microspheres for sustained intrapulmonary delivery.
  • To evaluate the interaction of these microspheres with biological membranes.
  • To assess the pulmonary absorption of moxifloxacin from chitosan microspheres.

Main Methods:

  • Spray-drying method with glutaraldehyde crosslinking for microsphere preparation.
  • In vitro drug release studies.
  • Differential scanning calorimetry (DSC) with dipalmitoylphosphatidylcholine (DPPC) liposomes as a biomembrane model.
  • In vitro bronchial epithelial cell model (Calu-3 cells) using Franz diffusion cells for absorption studies.

Main Results:

  • Microspheres were spherical, 2.5-6.0 microm in size, suitable for inhalation.
  • Sustained moxifloxacin release observed, enhanced by higher glutaraldehyde concentrations.
  • Crosslinked microspheres did not alter liposome properties, unlike uncrosslinked ones.
  • Pulmonary absorption studies showed reduced moxifloxacin permeation through Calu-3 cells for microsphere formulations compared to free drug.

Conclusions:

  • Chitosan microspheres provide sustained release of moxifloxacin for intrapulmonary administration.
  • Crosslinked microspheres demonstrate reduced interaction with biomembranes and delayed pulmonary absorption.
  • These findings suggest potential for developing controlled moxifloxacin pulmonary delivery systems using chitosan microspheres.